rxstat › Classes › Antimetabolites
Antimetabolites: shortage status in Canada
2 of the 12 antimetabolites rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.
Methotrexate (Nordimet) Partial shortage 3 of 31 reported products affected
Pemetrexed (Alimta) Partial shortage 4 of 12 reported products affected
Cytarabine Shortage anticipated 0 of 3 reported products affected
Gemcitabine Shortage anticipated 0 of 9 reported products affected
Raltitrexed (Tomudex) Shortage anticipated 0 of 1 reported products affected
Azacitidine No current shortage
Capecitabine (Xeloda) No current shortage
Cladribine No current shortage
Clofarabine (Clolar) No current shortage
Fludarabine No current shortage
Fluorouracil (Efudex) No current shortage
Mercaptopurine (Purinethol) No current shortage
Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.